{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060237","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.362312+00:00","generated_at":"2026-06-08T13:32:50.586637+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Standard BioTools Q3 revenue $25.4M, net loss $21M; raises outlook, merger with SomaLogic","bullets":["Q3 revenue $25.4M (down 1% YoY); GAAP net loss $21.0M; Non-GAAP adj. EBITDA -$10.1M.","Instrument sales grew 14% in Q3, 47% YTD; Non-GAAP gross margin expanded 830bps to 57.0%.","Operating cash use decreased 53% in Q3 to $12M; cash and investments $129.6M at quarter end.","Raised 2023 financial outlook; planned merger with SomaLogic cited to enhance revenue and accelerate path to profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060237","json":"https://secwatch.observer/filing/0000950170-23-060237.json","markdown":"https://secwatch.observer/filing/0000950170-23-060237.md","text":"https://secwatch.observer/filing/0000950170-23-060237.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000095017023060237/0000950170-23-060237-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000095017023060237/lab-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T13:32:50.586637+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}